Aigen Investment Management LP Invests $349,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Aigen Investment Management LP bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 1,138 shares of the company’s stock, valued at approximately $349,000.

A number of other hedge funds have also recently bought and sold shares of MEDP. Riverbridge Partners LLC lifted its stake in shares of Medpace by 7.1% in the fourth quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock valued at $199,975,000 after buying an additional 43,197 shares during the period. Invesco Ltd. grew its holdings in shares of Medpace by 67.6% during the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock worth $148,159,000 after purchasing an additional 246,775 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Medpace by 312.6% during the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after purchasing an additional 319,210 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of Medpace by 47.7% in the fourth quarter. Los Angeles Capital Management LLC now owns 254,125 shares of the company’s stock valued at $77,897,000 after purchasing an additional 82,068 shares in the last quarter. Finally, Northern Trust Corp raised its stake in shares of Medpace by 4.0% in the third quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock valued at $58,402,000 after purchasing an additional 9,192 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have weighed in on MEDP. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and lifted their price target for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Guggenheim upped their price objective on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird lifted their target price on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Finally, Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and boosted their target price for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Medpace currently has an average rating of “Moderate Buy” and an average price target of $443.00.

Insider Transactions at Medpace

In related news, CEO August J. Troendle sold 100,000 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Medpace news, Director Ashley M. Keating sold 250 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now directly owns 250 shares in the company, valued at approximately $102,467.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 145,291 shares of company stock worth $59,648,117. 20.30% of the stock is currently owned by company insiders.

Medpace Stock Performance

NASDAQ:MEDP traded down $0.03 on Friday, hitting $390.55. 112,402 shares of the stock were exchanged, compared to its average volume of 190,675. The stock has a market capitalization of $12.10 billion, a price-to-earnings ratio of 39.81, a P/E/G ratio of 1.93 and a beta of 1.40. Medpace Holdings, Inc. has a 52 week low of $199.20 and a 52 week high of $421.00. The company’s 50-day moving average price is $395.33 and its 200 day moving average price is $345.62.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The company had revenue of $511.00 million during the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter in the previous year, the company posted $2.27 EPS. The business’s revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 11.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.